MGB Biopharma Limited

23 articles about MGB Biopharma Limited

• MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)

  5/19/2020

  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives, announces that its Phase II clinical study has met its endpoints of safety, efficacy, and dose selection.

• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

  10/10/2019

  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.

• MGB Biopharma Announces Completion of Funding Round

  8/30/2019

  MGB Biopharma announces the completion of its latest funding round.

• MGB Biopharma – FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

  1/24/2019

  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces that the Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND/CTA) for its lead candidate MGB-BP-3

• MGB Biopharma Limited Closes $1 Million Financing Round To Finance Manufacturing Of MGB-BP-3 For Phase II Study In Clostridium Difficile-Associated Disease (CDAD)

  4/6/2017

• MGB Biopharma Limited Granted Qualified Infectious Disease Product (QIPD) Designation By U.S. FDA For The Treatment Of Clostridium Difficile-Associated Diarrhoea (CDAD) For MGB-BP-3

  9/12/2016

• MGB Biopharma Limited To Present Poster At Upcoming ASM Microbe Meeting In Boston On 20 June 2016

  6/14/2016

• MGB Biopharma Limited Welcomes Jim O’Neill’s Final Recommendations For The World To Defeat Superbugs

  5/19/2016

• MGB Biopharma Limited Welcomes Jim O'Neill's Final Recommendations For The World To Defeat Superbugs

  5/19/2016

• MGB Biopharma Limited's Pre-IND Meeting With FDA Provides Clear Guidelines On Further Development Of Oral MGB-BP-3, A Truly Novel Antibiotic Targeting Clostridium Difficile Infections

  5/9/2016

• MGB Biopharma Limited And University of Strathclyde Sign New Agreement To Develop Novel MGB Anti-Infectives To Tackle A Key Mechanism Of AMR

  2/15/2016

• MGB Biopharma Limited Successfully Completes Phase I Clinical Trial With Oral MGB-BP-3 – A Truly Novel Antibiotic Targeting Clostridium Difficile Infections

  12/8/2015

• MGB Biopharma Limited Successfully Completes Feasibility Study With Topical Formulation Of Its Lead Antibacterial MGB-BP-3

  11/17/2015

• MGB Biopharma Limited To Attend BIO-Europe 2015

  10/29/2015

• MGB Biopharma Limited Wins Scottish Business Award

  9/10/2015

• MGB Biopharma Limited Commences Phase I Clinical Trial With Oral Formulation Of MGB-BP-3 For The Treatment Of Multi-Resistant Clostridium Difficile Infections

  7/21/2015

• MGB Biopharma Limited Succeeds In Developing An IV Formulation Of MGB-BP-3 For The Treatment Of Systemic Susceptible And Resistant Gram-Positive Hospital-Acquired Infections

  6/2/2015

• MGB Biopharma Limited Continues To Progress Its Truly Novel Anti-Infectives Platform To Tackle Antibiotic Resistance In 2014

  1/12/2015

• MGB Biopharma Limited Secures $6.4 MillionTo Advance Its Novel Lead Antibacterial, MGB-BP-3, Into Clinical Development

  9/17/2014